Saint Kitts and Nevis vs Suriname: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Saint Kitts and Nevis
0.2%
in 2024
Suriname
0.2%
in 2024
Saint Kitts and Nevis rank
98th
Suriname rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Saint Kitts and Nevis
- Suriname
How they compare
Saint Kitts and Nevis currently reports 0.2% against 0.2% in Suriname, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Saint Kitts and Nevis ahead.
Saint Kitts and Nevis ranks 98th and Suriname ranks 98th of 246 countries.
Saint Kitts and Nevis has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Saint Kitts and Nevis | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.2% | 0.1% | Saint Kitts and Nevis |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Saint Kitts and Nevis or Suriname?
- Saint Kitts and Nevis, at 0.2% against 0.2% in Suriname as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Saint Kitts and Nevis and Suriname?
- 0.0%, with Saint Kitts and Nevis ahead.
- How many years of comparable data are there for Saint Kitts and Nevis and Suriname?
- 10 years are reported by both, from 2015 to 2024.
- How do Saint Kitts and Nevis and Suriname rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Saint Kitts and Nevis ranks 98th and Suriname ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.